Reach out to us, and we'll strive to match it
BDNF binds to the tropomyosin receptor kinase B (TrkB) receptor, promoting neuronal survival and plasticity through the activation of key intracellular signalling cascades, including the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt), phospholipase C- (PLC-), and mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathways [13,14]
Researchers recently reported findings indicating that patients using GLP 1 receptor agonists experienced higher rates of certain bone and joint conditions compared to non users
The most common adverse effects in trials are gastrointestinal nausea, vomiting, diarrhoea, and constipation consistent with other GLP-1-based therapies
The four-week intervals Each dose is held for four weeks before the next increase